S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
S&P 500   3,103.54 (-0.16%)
DOW   27,766.29 (-0.20%)
QQQ   201.70 (-0.22%)
MSFT   149.48 (-0.09%)
GOOGL   1,300.14 (-0.13%)
AMZN   1,734.71 (-0.62%)
CGC   20.29 (+15.02%)
NVDA   210.18 (-0.47%)
MU   45.55 (-0.04%)
BABA   184.86 (+1.38%)
GE   11.53 (+1.23%)
T   37.60 (+1.13%)
AMD   39.52 (-3.56%)
ACB   3.12 (+18.18%)
F   8.71 (-0.23%)
PRI   130.45 (-0.81%)
NFLX   311.69 (+2.14%)
BAC   32.84 (+0.46%)
GILD   65.73 (+1.31%)
DIS   146.90 (-0.02%)
Log in

Myriad Genetics Stock Price, Forecast & Analysis (NASDAQ:MYGN)

$25.11
+0.11 (+0.44 %)
(As of 11/21/2019 04:00 PM ET)
Today's Range
$24.82
Now: $25.11
$25.33
50-Day Range
$20.55
MA: $28.87
$35.03
52-Week Range
$20.10
Now: $25.11
$48.40
Volume451,100 shs
Average Volume1.13 million shs
Market Capitalization$1.87 billion
P/E Ratio19.47
Dividend YieldN/A
Beta0.96
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$851.10 million
Cash Flow$2.36 per share
Book Value$14.84 per share

Profitability

Net Income$4.60 million

Miscellaneous

Employees2,600
Market Cap$1.87 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.


Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Monday, November, 4th. The company reported $0.08 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.26 by $0.18. The business earned $186.30 million during the quarter, compared to the consensus estimate of $202.34 million. Myriad Genetics had a negative net margin of 1.83% and a positive return on equity of 6.48%. Myriad Genetics's revenue was down 7.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.43 EPS. View Myriad Genetics' Earnings History.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Myriad Genetics.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY20 earnings guidance on Monday, November, 4th. The company provided EPS guidance of $1.00-1.10 for the period, compared to the Thomson Reuters consensus estimate of $1.78. The company issued revenue guidance of $800-810 million, compared to the consensus revenue estimate of $872.74 million.

What price target have analysts set for MYGN?

8 Wall Street analysts have issued 12 month price targets for Myriad Genetics' shares. Their forecasts range from $18.00 to $35.00. On average, they anticipate Myriad Genetics' share price to reach $27.80 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for Myriad Genetics.

What is the consensus analysts' recommendation for Myriad Genetics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 2 sell ratings and 6 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Myriad Genetics.

Has Myriad Genetics been receiving favorable news coverage?

Media coverage about MYGN stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Myriad Genetics earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Myriad Genetics.

Are investors shorting Myriad Genetics?

Myriad Genetics saw a decrease in short interest during the month of October. As of October 15th, there was short interest totalling 10,680,000 shares, a decrease of 10.3% from the September 15th total of 11,910,000 shares. Based on an average daily trading volume, of 1,360,000 shares, the short-interest ratio is currently 7.9 days. Approximately 14.9% of the company's shares are short sold. View Myriad Genetics' Current Options Chain.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the folowing people:
  • Mr. Mark Christopher Capone, CEO, Pres & Director (Age 57)
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 48)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 60)
  • Mr. Richard M. Marsh, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Alexander Ford, Pres of Myriad Women's Health (Age 52)

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.13%), CWM LLC (0.80%), Russell Investments Group Ltd. (0.48%), Rhumbline Advisers (0.32%), Fisher Asset Management LLC (0.24%) and California Public Employees Retirement System (0.23%). Company insiders that own Myriad Genetics stock include Bernard Tobin, Dennis Langer, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard Bryan Riggsbee, Richard M Marsh and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Systematic Financial Management LP, Rice Hall James & Associates LLC, Stephens Inc. AR, Ingalls & Snyder LLC, SG Americas Securities LLC, Mackay Shields LLC and BB&T Corp. Company insiders that have sold Myriad Genetics company stock in the last year include Bernard Tobin, Gary A King, Ralph L Mcdade and Richard Bryan Riggsbee. View Insider Buying and Selling for Myriad Genetics.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was purchased by a variety of institutional investors in the last quarter, including CWM LLC, State of New Jersey Common Pension Fund D, Oppenheimer Asset Management Inc., Fisher Asset Management LLC, State of Alaska Department of Revenue, California Public Employees Retirement System, Envestnet Asset Management Inc. and 6 Meridian. View Insider Buying and Selling for Myriad Genetics.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $25.11.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $1.87 billion and generates $851.10 million in revenue each year. The company earns $4.60 million in net income (profit) each year or $1.29 on an earnings per share basis. Myriad Genetics employs 2,600 workers across the globe.View Additional Information About Myriad Genetics.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is http://myriad.com/.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]


MarketBeat Community Rating for Myriad Genetics (NASDAQ MYGN)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  419 (Vote Outperform)
Underperform Votes:  688 (Vote Underperform)
Total Votes:  1,107
MarketBeat's community ratings are surveys of what our community members think about Myriad Genetics and other stocks. Vote "Outperform" if you believe MYGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Featured Article: What is the QQQ ETF?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel